Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00505895 · ClinicalTrials.gov registry record · Phase 2

FM 140 vs FM100 Study in Patients With Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
Phase 2
Development phase
52
Enrollment target
1
Study location

NCT00505895: Completed Phase 2 study of Multiple Myeloma, sponsored by M.D. Anderson Cancer Center.

NCT00505895 is a Phase 2 study of Multiple Myeloma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 52 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00505895, a Phase 2 study of Multiple Myeloma, has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
52 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn if there is a difference in transplant outcomes between two different doses of melphalan given in combination with fludarabine followed by transfusion of a related or unrelated volunteer donor's peripheral blood or bone marrow progenitor cells (allogeneic stem cell transplant) in patients with multiple myeloma. This study will also look at whether treatment with a antibody called rituximab against a specific type of lymphocyte (B cell) will reduce the risks of developing graft versus host disease after transplant. The safety of these treatments will also be compared.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Fludarabine
  • DRUG Melphalan
  • DRUG Rituximab
  • PROCEDURE Stem Cell Infusion

Study Locations (1)

Texas

  • UT MD . Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2002-01
Est. Completion 2013-05
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00505895

The ClinicalTrials.gov registry entry for NCT00505895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Fludarabine is the first listed.

NCT00505895 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00505895 about?

NCT00505895 is a clinical study titled "FM 140 vs FM100 Study in Patients With Multiple Myeloma". The goal of this clinical research study is to learn if there is a difference in transplant outcomes between two different doses of melphalan given in combination with fludarabine followed by transfusion of a related or unrelated volunteer donor's peripheral blood or bone marrow progenitor cells (al...

What is the current status of trial NCT00505895?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2002-01. Estimated completion is 2013-05.

What conditions does trial NCT00505895 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT00505895?

The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), Rituximab (DRUG), Stem Cell Infusion (PROCEDURE).

Who is sponsoring clinical trial NCT00505895?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00505895 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.